PMID- 31564916
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220410
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 12
DP  - 2019
TI  - Long noncoding RNA ZEB2-AS1 facilitates laryngeal squamous cell carcinoma 
      progression by miR-6840-3p/PLXNB1 axis.
PG  - 7337-7345
LID - 10.2147/OTT.S212749 [doi]
AB  - PURPOSE: To investigate the role of zinc finger E‑box‑binding homeobox 2 
      antisense RNA 1 (ZEB2-AS1) in regulating laryngeal squamous cell carcinoma (LSCC) 
      progression. PATIENTS AND METHODS: In this retrospective study, we included all 
      patients who underwent a surgical operation at The First Hospital of Qiqihaer 
      City for LSCC. Then, we compared the expression of ZEB2-AS1 in LSCC tissues and 
      paired healthy tissues. Besides, we also performed a series of functional assays, 
      CCK8 assays, colony formation assays, and transwell assays to examine the 
      functions of LSCC cells after knockdown of ZEB2-AS1. Through bioinformatics 
      analysis, we predicted that ZEB2-AS1 binds to miR-6840-3p and targets PLXNB1. 
      RESULTS: We indicated that the expression of ZEB2-AS1 was higher in LSCC tissues 
      compared to the paired adjacent tissues, and ZEB2-AS1 was also highly expressed 
      in LSCC cell lines. Furthermore, we discovered that ZEB2-AS1 promoted cell 
      proliferation, migration and invasion and was associated with poor prognosis. To 
      find the mechanism, we performed bioinformatics analysis. We identified that 
      ZEB2-AS1 binds to miR-6840-3p and targets PLXNB1. Additionally, miR-6840-3p 
      overexpression or knockdown of PLXNB1 decreased the abilities of cell migration 
      and invasion. CONCLUSION: These findings demonstrated that overexpression of 
      ZEB2-AS1 promotes LSCC progression. Overexpression of miR-6840-3p or 
      downregulation of PLXNB1 can abrogate ZEB2-AS1-mediated LSCC malignant 
      development.
CI  - (c) 2019 Xu et al.
FAU - Xu, Qiushi
AU  - Xu Q
AD  - Ear Nose and Throat Department, Affiliated Qiqihar Hospital, Southern Medical 
      University, The First Hospital of Qiqihaer City, Guangzhou, Heilongjiang 161000, 
      People's Republic of China.
FAU - Liu, Hongyu
AU  - Liu H
AD  - Ear Nose and Throat Department, Affiliated Qiqihar Hospital, Southern Medical 
      University, The First Hospital of Qiqihaer City, Guangzhou, Heilongjiang 161000, 
      People's Republic of China.
FAU - Yu, Bing
AU  - Yu B
AD  - Pathology Department, Affiliated Qiqihar Hospital, Southern Medical University, 
      The First Hospital of Qiqihaer City, Guangzhou, Heilongjiang 161000, People's 
      Republic of China.
FAU - Chen, Wenjing
AU  - Chen W
AD  - Pathology Department, Affiliated Qiqihar Hospital, Southern Medical University, 
      The First Hospital of Qiqihaer City, Guangzhou, Heilongjiang 161000, People's 
      Republic of China.
FAU - Zhai, Lili
AU  - Zhai L
AD  - Pathology Department, Affiliated Qiqihar Hospital, Southern Medical University, 
      The First Hospital of Qiqihaer City, Guangzhou, Heilongjiang 161000, People's 
      Republic of China.
FAU - Li, XueYing
AU  - Li X
AD  - Ear Nose and Throat Department, Affiliated Qiqihar Hospital, Southern Medical 
      University, The First Hospital of Qiqihaer City, Guangzhou, Heilongjiang 161000, 
      People's Republic of China.
FAU - Fang, Yanchun
AU  - Fang Y
AD  - Pathology Department, Affiliated Qiqihar Hospital, Southern Medical University, 
      The First Hospital of Qiqihaer City, Guangzhou, Heilongjiang 161000, People's 
      Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20190906
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC6735660
OTO - NOTNLM
OT  - LSCC
OT  - PLXNB1
OT  - ZEB2-AS1
OT  - invasion
OT  - miR-6840-3p
OT  - migration
COIS- The authors report no conflicts of interest in this work.
EDAT- 2019/10/01 06:00
MHDA- 2019/10/01 06:01
PMCR- 2019/09/06
CRDT- 2019/10/01 06:00
PHST- 2019/04/18 00:00 [received]
PHST- 2019/07/31 00:00 [accepted]
PHST- 2019/10/01 06:00 [entrez]
PHST- 2019/10/01 06:00 [pubmed]
PHST- 2019/10/01 06:01 [medline]
PHST- 2019/09/06 00:00 [pmc-release]
AID - 212749 [pii]
AID - 10.2147/OTT.S212749 [doi]
PST - epublish
SO  - Onco Targets Ther. 2019 Sep 6;12:7337-7345. doi: 10.2147/OTT.S212749. eCollection 
      2019.